A phase IIIb randomized, double-blind, placebo controlled, 2 period crossover, multicenter study to assess the effect of indacaterol (150 microg o.d.) on exercise endurance in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Trial Profile

A phase IIIb randomized, double-blind, placebo controlled, 2 period crossover, multicenter study to assess the effect of indacaterol (150 microg o.d.) on exercise endurance in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Jan 2013

At a glance

  • Drugs Indacaterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Novartis Pharma
  • Most Recent Events

    • 21 Apr 2012 Planned number of patients changed from 83 to 96 as reported by EudraCT.
    • 21 Apr 2012 Additional trial location (Germany) identified as reported by EudraCT.
    • 08 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top